



Q2 2022 EARNINGS



Exact Sciences' strong second quarter results **reflect meaningful progress toward our vision** to help eradicate cancer by providing patients better information before diagnosis and throughout their treatment. **We're focusing on getting more people tested with Cologuard® and Oncotype®, prioritizing our highest impact projects to reach profitability, and generating high-quality evidence for our pipeline of cancer diagnostic tests.**

— KEVIN CONROY, CHAIRMAN & CEO



**GREAT PLACE TO WORK™
CERTIFIED FOR THE 4TH
CONSECUTIVE YEAR**



**SECURED AN IMPROVED
POSITION IN ASCO GUIDELINES
FOR ONCOTYPE DX BREAST
AS THE PREFERRED TEST FOR
EARLY-STAGE CANCER
PATIENTS**



**SCREENED MORE THAN 700K
PEOPLE FOR COLON CANCER
WITH COLOGUARD**



**IMPROVED PATH TO
PROFITABILITY AND CASH
LIQUIDITY POSITION, REDUCING
ADJUSTED EBITDA LOSS FROM
\$90M IN Q1 TO \$46M IN Q2**

PIPELINE PROGRESS

MADE PROGRESS TOWARD
COMPLETING BLUE-C, OUR
**PIVOTAL STUDY TO SUPPORT
OUR NEXT-GENERATION
COLOGUARD AND COLON
CANCER BLOOD TESTS**

**PUBLISHED EVIDENCE
SUPPORTING OUR
TUMOR-NAIVE MINIMAL
RESIDUAL DISEASE TEST IN
COLON CANCER**

**GENERATED ADDITIONAL
EVIDENCE FOR OUR
MULTI-CANCER EARLY
DETECTION TEST, TO BE
PRESENTED AT THE EUROPEAN
SOCIETY FOR MEDICAL
ONCOLOGY, SEPTEMBER 9-13**

EXACT SCIENCES BY THE NUMBERS

450



R&D TEAM
MEMBERS

1,300



PERSON
COMMERCIAL
TEAM

90



COUNTRY
PRESENCE

965K

PEOPLE
TESTED
IN 2Q22

cologuard®
oncotype dx®
oncomap® ExTra

FORWARD LOOKING STATEMENTS:

This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; our strategies, positioning, resources, capabilities and expectations for future events or performance; and the anticipated benefits of our acquisitions, including estimated synergies and other financial impacts.

Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: uncertainties associated with the coronavirus (COVID-19) pandemic, including its possible effects on our operations, including our supply chain and clinical studies, and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; our ability to meet our payment obligations under our indebtedness; our ability to raise additional capital in amounts and on terms satisfactory to us, if at all; our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; the amount and nature of competition for our products and services; the effects of any judicial, executive or legislative action affecting us or the healthcare system; recommendations, guidelines and quality metrics issued by various organizations regarding cancer screening or our products and services; our ability to successfully develop new products and services and assess potential market opportunities; our ability to effectively enter into and utilize strategic partnerships and acquisitions; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; our ability to manage an international business and our expectations regarding our international expansion and opportunities; the potential effects of changing macroeconomic conditions, including the effects of inflation and interest rate and foreign currency exchange rate fluctuations and any such efforts to hedge such effects; the possibility that the anticipated benefits from our business acquisitions will not be realized in full or at all or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of acquired businesses' operations or divestiture of business operations will be greater than expected and the possibility that integration or divestiture efforts will disrupt our business and strain management time and resources; the outcome of any litigation, government investigations, enforcement actions or other legal proceedings; our ability to retain and hire key personnel. The risks included above are not exhaustive. Other important risks and uncertainties are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.